Kathryn Flynn - Harvard Bioscience Corporate Controller
| HBIO Stock | USD 1.93 0.01 0.52% |
Executive
Kathryn Flynn is Corporate Controller of Harvard Bioscience
| Address | 84 October Hill Road, Holliston, MA, United States, 01746 |
| Phone | 508 893 8999 |
| Web | https://www.harvardbioscience.com |
Harvard Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.0198) % which means that it has lost $0.0198 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.204) %, meaning that it created substantial loss on money invested by shareholders. Harvard Bioscience's management efficiency ratios could be used to measure how well Harvard Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of January 2025, Return On Tangible Assets is likely to drop to -0.05. In addition to that, Return On Capital Employed is likely to drop to 0.02. At this time, Harvard Bioscience's Other Current Assets are very stable compared to the past year. As of the 18th of January 2025, Intangible Assets is likely to grow to about 21.5 M, while Total Assets are likely to drop about 124.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Christian Voigtlander | ICU Medical | 57 | |
| Sarah Comstock | Merit Medical Systems | N/A | |
| Marcena Clawson | Utah Medical Products | N/A | |
| Christopher Pazdan | Repro Med Systems | N/A | |
| Ricardo Alvarez | Merit Medical Systems | N/A | |
| Addam Chupa | InfuSystems Holdings | 46 | |
| Priyam Shah | Akoya Biosciences | N/A | |
| Mark Fox | Utah Medical Products | N/A | |
| Rob Cannon | Repro Med Systems | N/A | |
| Jonathan Ngau | LeMaitre Vascular | 51 | |
| Brian Koopman | Utah Medical Products | 55 | |
| David Hissong | LeMaitre Vascular | N/A | |
| Scott Centea | AngioDynamics | 45 | |
| Kenneth Miller | Repro Med Systems | 56 | |
| Andy Molnar | Milestone Scientific | 62 | |
| Clay Fradd | ICU Medical | N/A | |
| Thomas Adams | Repro Med Systems | 52 | |
| Jerod Funke | InfuSystems Holdings | 50 | |
| Juan Serna | AngioDynamics | N/A | |
| Niro Ramachandran | Akoya Biosciences | 50 | |
| James JD | Milestone Scientific | N/A | |
Management Performance
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0198 |
Harvard Bioscience Leadership Team
Elected by the shareholders, the Harvard Bioscience's board of directors comprises two types of representatives: Harvard Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Harvard. The board's role is to monitor Harvard Bioscience's management team and ensure that shareholders' interests are well served. Harvard Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Harvard Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ryan Wallace, Senior Sales | ||
| Michael Rossi, Chief Officer | ||
| Kara Weiner, VP Management | ||
| David Sirois, Director Reporting | ||
| Kenneth Olson, Ex Officer | ||
| Kathryn Flynn, Corporate Controller | ||
| James Green, CEO President | ||
| John Fry, Chief Secretary | ||
| David Balcom, Senior Operations | ||
| John JD, Chief Secretary | ||
| CGMA CPA, CFO Treasurer | ||
| Lori Packer, Vice Operations |
Harvard Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Harvard Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0198 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 124.87 M | ||||
| Shares Outstanding | 43.62 M | ||||
| Shares Owned By Insiders | 7.22 % | ||||
| Shares Owned By Institutions | 75.68 % | ||||
| Number Of Shares Shorted | 654.38 K | ||||
| Price To Earning | (25.00) X |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.33) | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.